Within this evolving world of biopharma, it is estimated that two-thirds of biopharmaceutical manufacturing is outsourced. Therefore, the supply
chain is not only complex, but also largely virtual for pharmaceutical companies bringing their therapies through clinical development and
ultimately to market. James Klingelhoefer at Pelican BioThermal establishes the missing ingredient in the CDO/CDMO offering.